Alzheimer’s disease is devastating for both patients and their families. As the population ages, this disease also places a disproportionate financial burden on society, and costs are expected to spiral over the next decade. Potential new therapies are beginning to target early stages of disease, even before symptoms are present, as well as targeting existing symptomatology. As a result, payers will need to explore new approaches to identify potential patient populations and re-evaluate the types of evidence that define treatment success. In collaboration with The Global CEO Initiative on Alzheimer’s Disease (CEOi), the Duke-Margolis Center for Health Policy convened this expert workshop to understand how to better capture meaningful outcomes for patients and caregivers that could inform future payment models.